ArieSBelldegrunMD

Chief of the Division of Urologic Oncology and Director of Urologic Research in the Department of Urology at the University of California, Los Angeles. He is a UCLA Professor of Urology, Clinical Director of the UCLA Prostate Disease Research Program and Surgical Director of the UCLA Kidney Cancer Program. He is also the Founder and Chairman of the Board of Agensys, Inc

Join to view full profile

Dr. Belldegrun is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Belldegrun's full profile

Already have an account?

Office
200 Medical Plz
Ste 140
Los Angeles, CA 90095
Phone+1 310-794-7700

Fax+1 310-301-8751

Education & Training

Clinical Center at the National Institutes of HealthResidency, Urology, 1987 - 1988
Clinical Center at the National Institutes of HealthResidency, Surgery, 1985 - 1987
Brigham and Women's Hospital/Harvard Medical SchoolResidency, Urology, 1982 - 1985
The Hebrew University of Jerusalem Hadassah Medical SchoolClass of 1975

Certifications & Licensure

NY State Medical License 1987 - 2026
CA State Medical License 1988 - 2025
MA State Medical License 1983 - 2003
VA State Medical License 1985 - 2000

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Top Doctors:LA Area Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer Start of enrollment: 1999 Jun 01
Terminated
Phase 2
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer Start of enrollment: 2000 Apr 01
Completed
Phase 1
Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer Start of enrollment: 2000 Nov 01
Terminated
Phase 1, Phase 2
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 2000 Dec 01
Unknown status
Phase 1
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2002 Nov 01
Completed
Phase 2
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Start of enrollment: 2004 Jul 01
Completed
Phase 3
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer Start of enrollment: 2004 May 01
Completed
Phase 2
Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer Start of enrollment: 2005 Nov 01
Completed
Not Applicable
Open-label Extension Study of the Effects of Pomegranate Extract on Rising PSA After Primary Therapy for Prostate Cancer Start of enrollment: 2008 Feb 01
Unknown status
Phase 2
Extension to Study of Effects of Pomegranate Extract on Rising PSA Levels After Primary Therapy for Prostate Cancer Start of enrollment: 2007 Dec 01
Unknown status
Phase 2
Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy Start of enrollment: 2006 Jun 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

29 citations
A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer
Nicholas M. Donin, Karim Chamie, Andrew T. Lenis, Allan J. Pantuck, Madhu Reddy
Urologic Oncology. 2017-02-01
567 citations
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.
Nicolette Janzen, Hyung L. Kim, Robert A. Figlin, Arie S. Belldegrun
The Urologic Clinics of North America. 2003-11-01
29 citations
Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma.
Andrew T. Lenis, Nicholas M. Donin, Izak Faiena, Amirali Salmasi, David W. Johnson
Urologic Oncology. 2018-01-01

Press Mentions

New Imaging Technique Accurately Detects Aggressive Kidney Cancer, Claims StudyOctober 21st, 2024
New Imaging Technique Accurately Detects Aggressive Kidney CancerOctober 3rd, 2024
Billionaire Surgeon Donates $120M to UCLAAugust 28th, 2024
Join now to see all